Compression Therapy Market Size & Share, by Material (Synthetic, Natural); Technology; Product Type; Distribution Channel; End user; Application - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Compression Therapy Market - Regional Analysis

North America Market Insights

North America market is dominating and is expected to hold the regional revenue share of 38.7% by 2035. The market is defined by high technological adoption, stringent regulatory oversight, and a well-established reimbursement framework. The dominant drivers include an aging demographic, a high prevalence of obesity and diabetes conditions that significantly increase the risk of venous disease, and robust clinical guidelines mandating compression for postoperative venous thromboembolism prophylaxis in surgical settings. The key trend is the shift of care from inpatient to home settings, supported by the reimbursement policies. This drives the demand for advanced patient-applied devices and retail-grade compression wear. Overall, the market is consolidated, with major players competing on portfolio breadth, clinical evidence, and direct integration into value-based care pathways.

In the U.S. compression therapy market, the demand is supported by the regulatory clearances, high chronic disease prevalence, and growing surgical volumes. In April 2023, the U.S. FDA granted the 510 (k) clearance to AIROS Medical for its AIROS 8P sequential compression system, including the expanded garment indication for truncal and abdominal swelling, indicating a continued regulatory support for advanced compression solutions in lymphedema and venous care. Besides, the disease prevalence remains the major utilization driver. As per the NLM October 2025 study, 1 in 100,000 individuals in the U.S. are affected by lymphedema, while millions more suffer from chronic venous insufficiency conditions routinely managed with compression therapy. Additionally, the CDC November 2024 data indicates that the total diabetes prevalence at 15.8%, increasing the risk of venous edema, venous complication and post surgical swelling that require compression-based management. Overall, the prevention of these diseases is strengthening sustained institutional procurement across hospitals and outpatient centers.

Relevance of Regulatory and Clinical Announcements to the U.S.

Source: AIROS Medical, Jiale Health Technology Shenzhen Co., Ltd., Koya Medical, Jiangsu MaxF Electric Appliance Co., Ltd, Cytokinetics

The market in Canada is supported by the publicly funded healthcare delivery, aging demographics, and the rising utilization of community-based care for chronic conditions. According to Statistics Canada's September 2025 data, adults aged 65 years and older accounted for 19.5% of the population in 2025, expanding the patient base for venous lymphatic and mobility-related care routinely managed with compression therapy. The World Bank December 2025 data shows that the current healthcare expenditure is 11.31% GDP in Canada. Besides the Health Canada maintains the medical device licensing pathways aligned with the international regulatory standards, supporting the consistent market access for compression therapy devices across provinces. These trends indicate a stable market demand in Canada.

APAC Market Insights

The Asia Pacific compression therapy market is growing rapidly and is defined by the high growth potential driven by diverse but converging factors. The primary driver is the rapid expansion and modernization of healthcare infrastructure, increasing access to medical devices. This is complemented by rising healthcare expenditure from both public and private sector growing awareness of chronic venous diseases, and a surging burden of aging populations, diabetes, and obesity. The surgical volume is also rising significantly, increasing the need for VTE prophylaxis. Moreover, the key trends include the local manufacturing and regulatory harmonization efforts, such as those by the ASEAN Medical Device Directive, to lower costs and improve access. The market is seeing a shift from basic elastic bandages to more advanced gradient compression garments and pneumatic devices, mainly in urban hospital settings.

India’s market is emerging steadily and is supported by a growing burden of chronic vascular conditions, rising surgical volumes, and expanding public investment in hospital and community healthcare infrastructure. According to the NLM March 2024 study, the non-communicable diseases account for over 60% of the total deaths in India, with diabetes, cardiovascular disease, and obesity increasing the incidence of venous insufficiency, edema, and chronic wounds that require compression-based management. Moreover, the Ayushman Bharat PM JAY scheme is publicly funded inpatient and post acute care, including the surgical procedures, where compression therapy is routinely used for edema control and thrombosis prevention. Besides, the UNFPA 2023 data shows that the people aged above 60 represent 1.1 billion of the total population, driving the demand for non-invasive therapies in home and outpatient settings. Together, expanding public coverage, demographic aging, and rising chronic disease prevalence are strengthening the long-term demand outlook for compression therapy across Indian hospitals, ambulatory centers, and home healthcare providers.

The high and growing burden of varicose vein disease and the rapid adoption of minimally invasive treatments, such as radiofrequency ablation and endovenous laser ablation, are driving the market in China. Moreover, the compression therapy has replaced the traditional high ligation and stripping due to faster recovery and lower complication rates. As per the NLM study in October 2023, compression therapy is a standard adjuvant after thermal ablation to support the vein occlusion, reduce postoperative pain, and limit bruising. With varicose veins affecting an estimated 10–30% of the adult population and prevalence increasing with age, the expanding elderly demographic is driving a large procedural volume across tertiary and regional hospitals. Moreover, the study depicts that the short-term compression for about 24 hrs to 48 hrs reflects a broader shift toward simplified patient-centric care pathways aimed at improving compliance. These findings highlight a sustained growth in China’s compression therapy market within hospital, ambulatory, and home-care settings.

Europe Market Insights

The compression therapy market in Europe is growing significantly and is defined by a mature healthcare infrastructure rapidly aging population, and universal health coverage models. These factors create a stable and expanding patient base for the lymphatic and chronic venous conditions. Moreover, the growth is fundamentally driven by the demographic pressures and high prevalence of obesity and diabetes as key factors. Further, the demand is propelled by the stringent national clinical guidelines promoting compression as the first-line treatment for venous leg ulcer and post surgical VTW prophylaxis. Moreover, the market is shifting towards the patient friendly products to support home-based care models, reducing the hospital burden via active outpatient management and digital health integration.

Strong clinical evidence, high outpatient surgical activity, and statutory reimbursement under the public health insurance system are driving the market in Germany. According to the NLM study in March 2024, clinical evidence based on 12 randomized controlled trials demonstrates that compression therapy, when added to the pharmacological treatment during the acute phase of lower limb deep venous thrombosis, results in significantly faster pain reduction and reduced limb swelling. Further multiple randomized controls show that the medical compression stockings reduce the incidence and severity of post-thrombotic syndrome by 16% to 27%, confirming a relative risk reduction of 34%. These findings align with Germany’s guideline-driven healthcare system, where therapies supported by strong clinical evidence are routinely reimbursed under the statutory health insurance (GKV). Further Germany’s high burden of venous disease and emphasis on outpatient vascular care, this level of validated efficacy supports sustained demand for compression therapy across hospitals, vascular clinics, and ambulatory care settings.

The compression therapy market in UK is positioned for steady growth supported by the regulatory approvals, rising venous disease burden, and NHS-led adoption of advanced wound and thrombosis prevention solutions. The EU and UK regulatory approval of ConvoMatrix in September 2025 strengthens the UK market by expanding the treatment options for venous leg ulcers and diabetic foot ulcers, conditions where compression therapy is routinely used along with advanced wound dressing. Besides the recent development in October 2025 by the international launch of Cardinal Health’s Kendall SCD SmartFlow compression system, which reinforces the demand for intermittent pneumatic compression in UK hospitals, mainly for deep vein thrombosis and pulmonary embolism prevention. These developments align with NHS England’s focus on reducing VTE-related complications, improving outpatient and community wound care outcomes, and supporting continued growth of compression therapy utilization across UK hospitals, outpatient clinics, long-term care facilities, and home care settings.